Farrer Park Hospital Enhances Dementia services to Better Guide Management and Care Plan for People with Dementia
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- Farrer Park Hospital ("FPH" or "the Hospital") today announced that the Hospital has enhanced its dementia services to offer an enhanced artificial intelligence (AI)-supported MRI screening tool for dementia. Dementia is a neurodegenerative disease that occurs due to abnormal brain changes. According to HealthHub, about one in 10 (amongst the elderly aged 60...
Fullerton Health launches DigiHealth Kiosk to improve accessibility and affordability of healthcare for Migrant Workers
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- The COVID 19 Pandemic has shown the importance of primary care for all segments of society, including Migrants Workers. Miah Ratan, 33, Maintenance Supervisor Sashtha Construction, first user of the Fullerton DigiHealth Kiosk at North Coast Lodge. Fullerton Health...
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at...
RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
STOCKHOLM, Sept. 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on Sep 20th , 2021, that its clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and that no additional patients will be screened after this week. Top-line results of the study are estimated to be...
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company's Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International Parkinson...
ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem
A fully connected and integrated approach keeps ZEISS at the forefront of ophthalmology with new data management innovations across devices, workflow solutions and software applications. JENA, Germany and DUBLIN, Calif., Sept. 20, 2021 /PRNewswire/ -- At ZEISS Innovation Week, September 21- 23, 2021, ZEISS Medical Technology will introduce industry-first, integrated solutions that bring further value to the ZEISS Medical Ecosystem, connecting...
PharmAbcine to Participate in BIO-Europe 2021
DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will take place from October 25 - 28, 2021. BIO-Europe is Europe's largest annual partnering conference serving...
CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2021...
The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile In August 2021, the National Medical Products Administration (NMPA) of China accepted the new drug application (NDA) of ivosidenib for the treatment of adults...
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept. 20, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF)...
P&G partners with Philippine Red Cross for COVID-19 Bakuna Buses in CALABARZON
MANILA, Philippines, Sept. 20, 2021 /PRNewswire/ -- Procter & Gamble (P&G) Philippines continues stepping up as a force for good by supporting the Philippine Red Cross (PRC) mission to assist in the government's national COVID-19 vaccination program. P&G recently donated over 5 million pesos to fund PRC COVID-19 Mobile...
